Trials / Completed
CompletedNCT00651599
Treatment of Vasomotor Symptoms in Korean Post Menopausal Women
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Investigating the Efficacy and Tolerability of Angeliq(drospirenon2mg and Estradiol 1mg) in Postmenopausal Korean Women With Vasomotor Symptoms Over 3, 28 Day Treatment Cycle
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 90 (actual)
- Sponsor
- Bayer · Industry
- Sex
- Female
- Age
- 45 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Study to demonstrate that the therapeutic efficacy of Angeliq® is better than placebo in Korean postmenopausal women with hot flushes and other climacteric symptoms. Safety and tolerability of Angeliq.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Angeliq (Drospirenone/17ß-estradiol, BAY86-4891) | Treatments will be administered daily, orally during the whole treatment period of 16 weeks without a treatment-free interval. |
| DRUG | Placebo | Placebo treatments will be administered daily, orally during the whole treatment period of 16 weeks without a treatment-free interval. |
Timeline
- Start date
- 2004-07-01
- Completion
- 2005-05-01
- First posted
- 2008-04-03
- Last updated
- 2014-12-31
Locations
4 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT00651599. Inclusion in this directory is not an endorsement.